Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Holst JM, Plesner TL, Pedersen MB, Frederiksen H, Møller MB, Clausen MR, et al. Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. Haematologica. 2020;105(10):2432-2439.

Kudo Y, Sugimoto M, Arias E, Kasashima H, Cordes T, Linares JF, et al. PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. Cancer Cell. 2020;38(2):247-262.e11.

Lui GY, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988.

Alam T, Agrawal S, Severin J, Young RS, Andersson R, Arner E, et al. Comparative transcriptomics of primary cells in vertebrates. Genome Res. 2020;30(7):951-961.

Haas T, Cushing MM. Hemostatic Balance in Severe Trauma. Front Pediatr. 2020;8:600501.

Aravena C, Patel J, Goyal A, Jaber W, Khemasuwan D, Machuzak M, et al. Role of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis and Management of Mediastinal Cyst. J Bronchology Interv Pulmonol. 2020;27(2):142-146.

Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020;33(11):2156-2168.

Geyer JT, Margolskee E, Krichevsky SA, Cattaneo D, Boiocchi L, Ronchi P, et al. Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. Haematologica. 2020;105(5):e221-e224.

Droesch C, Do MH, DeSancho M, Lee E-, Magro C, Harp J. Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19. JAMA Dermatol. 2020;156(9):1-3.

Zviran A, Schulman RC, Shah M, Hill ST, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26(7):1114-1124.